TRT and red blood cell increase: what the hematocrit data actually shows
Quick answer
Testosterone therapy consistently raises hematocrit through erythropoietin-mediated erythropoiesis, and the Endocrine Society recommends hematocrit monitoring at baseline, three months, six months, and annually thereafter, with dose reduction or phlebotomy indicated if levels exceed 54%. The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no significant increase in major adverse cardiovascular events in monitored men on TRT, but did identify an elevated pulmonary embolism rate, suggesting that hematocrit alone is an incomplete surrogate for thromboembolic risk. Patients with underlying thrombophilia, polycythemia, or untreated sleep apnea require more individualized risk assessment before and during TRT.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @sexedtok actually say?
The creator explained that testosterone replacement therapy causes the body to produce more red blood cells, which raises hematocrit, defined accurately as "the percentage of your blood that's made up of red blood cells." They warned that elevated hematocrit makes blood "quote unquote thick," increasing clot risk, and that their clinic checks hematocrit every three months. That's a reasonable, plain-language summary of a real clinical concern. The framing is practical and patient-facing, not alarmist.
The video appears to come from a clinic setting, which gives it a grounded, educational tone. Nothing here is promotional or reckless. The core message, that high hematocrit on TRT needs monitoring, is sound. But a few details deserve more scrutiny before patients walk away thinking they fully understand the risk picture.
Does the science back this up?
Yes, mostly. Testosterone stimulates erythropoiesis through erythropoietin signaling, and elevated hematocrit on TRT is well-documented. The claim that this raises clot risk is biologically plausible, but the actual magnitude of that risk in men on monitored TRT is more contested than the video suggests.
A 2023 randomized controlled trial by Lincoff et al. in the New England Journal of Medicine (TRAVERSE trial) found no statistically significant increase in major adverse cardiovascular events in hypogonadal men on testosterone therapy versus placebo, though it did find a higher rate of pulmonary embolism in the testosterone group. Separately, Glueck et al. (2014, Clinical and Applied Thrombosis/Hemostasis) documented venous thromboembolism cases tied to TRT, often in men with underlying thrombophilia. So the risk is real, but it is not uniform across all patients. The video's framing, "blood clots are bad," is accurate but stripped of the nuance that most healthy, monitored men on appropriate doses do not experience these events.
What did they get wrong (or right)?
They got the fundamentals right. The hematocrit definition is correct. The mechanism, more testosterone drives more red blood cell production, is accurate. The three-month monitoring interval is consistent with Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism), which recommend checking hematocrit at three and six months, then annually.
What's missing is a threshold. The video never mentions what "too high" actually means. Most clinicians flag concern at hematocrit above 52-54%, with some guidelines setting 54% as a hard stop for dose adjustment or phlebotomy. Without that number, patients leave with vague anxiety rather than actionable information. The video also skips viscosity entirely as a mechanism. "Thick blood" is not wrong, but the actual hemodynamic issue is increased blood viscosity reducing microvascular flow, which is distinct from simply having more red cells. That distinction matters for patients who want to understand their own labs.
What should you actually know?
If you are on TRT, hematocrit monitoring is not optional. It is a standard part of responsible prescribing. The Endocrine Society recommends withholding or reducing testosterone if hematocrit exceeds 54%, and therapeutic phlebotomy is sometimes used to bring levels down. Some clinicians also evaluate for sleep apnea, which independently raises hematocrit and is common in the same population seeking TRT.
The TRAVERSE trial (Lincoff et al., 2023, NEJM) is worth knowing about. It is the largest randomized trial of TRT cardiovascular outcomes to date. It did not show a spike in heart attacks or strokes, but it did show a pulmonary embolism signal. That is not a reason to panic, but it is a reason to be honest about what monitoring actually catches and what it does not. Hematocrit alone does not capture clotting factor changes or platelet activation. Patients with personal or family history of clotting disorders should have that conversation explicitly with their prescriber before starting TRT, not after a lab flag.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT and red blood cell increase: what the hematocrit data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TRT and red blood cell increase: what the hematocrit data actually shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Testosterone therapy consistently raises hematocrit through erythropoietin-mediated erythropoiesis, and the Endocrine Society recommends hematocrit monitoring at baseline, three months, six months, and annually thereafter, with dose reduction or phlebotomy indicated if levels exceed 54%.
FormBlends verdict
Testosterone therapy consistently raises hematocrit through erythropoietin-mediated erythropoiesis, and the Endocrine Society recommends hematocrit monitoring at baseline, three months, six months, and annually thereafter, with dose reduction or phlebotomy indicated if levels exceed 54%. The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no significant increase in major adverse cardiovascular events in monitored men on TRT, but did identify an elevated pulmonary embolism rate, suggesting that hematocrit alone is an incomplete surrogate for thromboembolic risk. Patients with underlying thrombophilia, polycythemia, or untreated sleep apnea require more individualized risk assessment before and during TRT.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Testosterone therapy consistently raises hematocrit through erythropoietin-mediated erythropoiesis, and the Endocrine Society recommends hematocrit monitoring at baseline, three months, six months, and annually thereafter, with dose reduction or phlebotomy indicated if levels exceed 54%. The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no significant increase in major adverse cardiovascular events in monitored men on TRT, but did identify an elevated pulmonary embolism rate, suggesting that hematocrit alone is an incomplete surrogate for thromboembolic risk. Patients with underlying thrombophilia, polycythemia, or untreated sleep apnea require more individualized risk assessment before and during TRT.
- The Endocrine Society (Bhasin et al., 2018) recommends hematocrit testing at 3 months, 6 months, and annually on TRT. Three-month monitoring is guideline-consistent.
- Most guidelines set 54% hematocrit as the threshold for dose reduction or therapeutic phlebotomy. The video never mentions this number, which is the most useful piece of information for a patient.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The Endocrine Society (Bhasin et al., 2018) recommends hematocrit testing at 3 months, 6 months, and annually on TRT. Three-month monitoring is guideline-consistent.
- Most guidelines set 54% hematocrit as the threshold for dose reduction or therapeutic phlebotomy. The video never mentions this number, which is the most useful piece of information for a patient.
- The TRAVERSE trial (Lincoff et al., 2023, NEJM), the largest RCT of TRT cardiovascular outcomes, found no significant increase in heart attack or stroke in monitored hypogonadal men on testosterone.
- The same TRAVERSE trial did find a statistically significant increase in pulmonary embolism in the testosterone group, meaning hematocrit monitoring catches one risk but does not fully capture thromboembolic exposure.
- Untreated obstructive sleep apnea independently raises hematocrit and is common in men seeking TRT. Screening for it is part of responsible pre-treatment workup, not just post-treatment lab monitoring.
- Men with personal or family history of thrombophilia face a meaningfully different risk profile on TRT and should be evaluated for clotting disorders before starting, not flagged only if hematocrit rises.
- Elevated hematocrit is the most common lab abnormality on TRT. Glueck et al. (2014, Clinical and Applied Thrombosis/Hemostasis) documented VTE cases tied to TRT, largely in men with pre-existing thrombophilia, reinforcing that baseline risk matters.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Maze Sexual Health · TikTok creator
6.0K views on this video
Replying to @AntCorp91 One of the most important side effects of testosterone replacement therapy can be an increase in the number of red blood cells (RBC’s) in the blood itself. The percentage of the blood made up by the RBCs is called the “hematocrit.” RBC’s carry the oxygen, and thus increasing the RBCs increases the oxygen carrying capacity of the blood. Because it increases their number of RBC’s, men with anemia (low percentage of RBC’s in the bloodstream) often benefit from TRT. We have
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Maze Sexual Health, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.